Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP1LC3B | Q9GZQ8 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 11/20 | 0.53 |
| ▸ | MAPT | P10636 | 3/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 3/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | CA12 | O43570 | 1/20 | 0.46 |
| ▸ | ALDH2 | P05091 | 1/20 | 0.46 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.46 |
| ▸ | MAOA | P21397 | 1/20 | 0.46 |
| ▸ | MAOB | P27338 | 1/20 | 0.46 |
| ▸ | HSD17B3 | P37058 | 1/20 | 0.46 |
| ▸ | SORD | Q00796 | 1/20 | 0.46 |
| ▸ | CA9 | Q16790 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30109506 | 1.00 | MAP1LC3B (0.57) | MAP1LC3BALDH1A1MAPTSMN1; SMN2MAPK1 | |
| SCHEMBL31282263 | 0.88 | ALDH1A1 (0.56) | MAP1LC3BALDH1A1MAPTSMN1; SMN2MAPK1 | |
| SCHEMBL23964527 | 0.81 | MAP1LC3B (0.56) | MAP1LC3BALDH1A1MAPTSMN1; SMN2MAPK1 | |
| SCHEMBL23964460 | 0.80 | MAP1LC3B (0.54) | MAP1LC3BALDH1A1MAPTSMN1; SMN2MAPK1 | |
| SCHEMBL23964326 | 0.78 | MAP1LC3B (0.44) | MAP1LC3BALDH1A1MAPTSMN1; SMN2MAPK1 | |
| SCHEMBL23964474 | 0.77 | MAP1LC3B (0.51) | MAP1LC3BALDH1A1MAPTSMN1; SMN2MAPK1 | |
| SCHEMBL31466697 | 0.75 | MAPT (0.46) | MAP1LC3BALDH1A1MAPTSMN1; SMN2MAPK1 | |
| SCHEMBL26172949 | 0.74 | ALDH1A1 (0.44) | MAP1LC3BALDH1A1MAPTSMN1; SMN2MAPK1 | |
| SCHEMBL30109387 | 0.74 | ALDH1A1 (0.44) | MAP1LC3BALDH1A1MAPTSMN1; SMN2MAPK1 | |
| SCHEMBL3787335 | 0.74 | MAP1LC3B (1.00) | MAP1LC3BALDH1A1MAPTSMN1; SMN2MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230181744-A1 | COMPOUND FOR PREVENTING OR TREATING LIPID METABOLISM-RELATED DISEASES | FUDAN UNIVERSITY (CN) | 2023-06-15 | — | — | US | disclosed |
| US-20230181744-A1 | COMPOUND FOR PREVENTING OR TREATING LIPID METABOLISM-RELATED DISEASES | FUDAN UNIVERSITY (CN) | 2023-06-15 | — | — | US | disclosed |
| EP-4155294-A1 | COMPOUND FOR PREVENTING OR TREATING LIPID METABOLISM-RELATED DISEASES | Fudan University (CN) | 2023-03-29 | — | — | EP | disclosed |
| WO-2021213518-A1 | COMPOUND FOR PREVENTING OR TREATING LIPID METABOLISM-RELATED DISEASES | 复旦大学 (CN) | 2021-10-28 | — | — | WO | disclosed |
| WO-2021213518-A1 | COMPOUND FOR PREVENTING OR TREATING LIPID METABOLISM-RELATED DISEASES | 复旦大学 (CN) | 2021-10-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230181744-A1 | COMPOUND FOR PREVENTING OR TREATING LIPID METABOLISM-RELATED DISEASES | MAP1LC3B, MAP1LC3A, SQSTM1 | MAP1LC3B 1/4885ALDH1A1 897/4885MAPT 15/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.